<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02789878</url>
  </required_header>
  <id_info>
    <org_study_id>NP 779/15</org_study_id>
    <nct_id>NCT02789878</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer</brief_title>
  <official_title>Phase II Study of Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for Patients With High-Risk Localized Prostate Cancer Prior to Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto do Cancer do Estado de São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized study to evaluate the efficacy and safety neoadjuvant androgen&#xD;
      deprivation therapy with goserelin and abiraterone with or without apalutamide prior to&#xD;
      radical prostatectomy for patients diagnosed with localized high-risk prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the prostate specific antigen (PSA) era, about 15% to 20% of patients are diagnosed with&#xD;
      high-risk localized disease and radical prostatectomy is a standard therapy for this subgroup&#xD;
      of patients. However, despite best local therapy, about 30-60% of high-risk patients will&#xD;
      eventually develop biochemical relapse and a significant proportion of these patients may&#xD;
      progress with metastatic disease and die from prostate cancer. Currently, there is no data&#xD;
      supporting the use of neoadjuvant therapy for patients with high-risk disease since studies&#xD;
      failed to demonstrate clinically significant benefit with standard androgen deprivation&#xD;
      therapy (ADT). Following improved outcomes in other malignancies with the use of neoadjuvant&#xD;
      therapy with active drugs in the metastatic setting, there is a growing interest in&#xD;
      evaluating new-generation androgen receptor (AR)-targeted therapy in earlier stages of&#xD;
      prostate cancer. Therefore, the goal of this study is to evaluate the efficacy and safety of&#xD;
      neoadjuvant therapy with ADT and abiraterone versus maximal androgen blockade using ADT,&#xD;
      abiraterone and apalutamide for patients with high-risk localized prostate cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 24, 2019</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic response</measure>
    <time_frame>3 months</time_frame>
    <description>To compare the rate of pathologic complete response (pCR) or pathologic near complete response (pnCR), defined as less than 0,5 cm of residual tumor in the prostatectomy specimen after neoadjuvant therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Residual cellularity rate</measure>
    <time_frame>3 months</time_frame>
    <description>To compare the rate of residual cellularity ≤ 30% in the prostatectomy specimen after neoadjuvant therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic downgrading</measure>
    <time_frame>3 months</time_frame>
    <description>To compare the rate of pathologic downgrading to ≤ ypT2N0 in the prostatectomy specimen after neoadjuvant therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA decline rate</measure>
    <time_frame>3 months</time_frame>
    <description>To compare the rate of PSA decline ≥ 50% and 90% after 3 months of neoadjuvant therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of positive surgical margins</measure>
    <time_frame>3 months</time_frame>
    <description>To compare the rate of positive surgical margins in the prostatectomy specimen after neoadjuvant therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of undetectable PSA</measure>
    <time_frame>12 months</time_frame>
    <description>To compare the rate of patients with undetectable PSA 12 months after radical prostatectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Grade ≥ 3 CTCAE adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>To compare the rate of CTCAE grade 3 or higher adverse events of the neoadjuvant therapy arms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of Magnetic Resonance Image Downstaging after Neoadjuvant Therapy</measure>
    <time_frame>3 months</time_frame>
    <description>To compare the MR image downstaging after neoadjuvant therapy with pathologic analysis of the prostatectomy specimen</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory analysis to correlate tissue expression of PSA, CYP17, Ki67, and AR with pathologic response.</measure>
    <time_frame>3 months</time_frame>
    <description>To correlate the expression of PSA, CYP17, Ki67, and AR by immunohistochemistry with pCR/npCR in the prostatectomy specimen.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ADT and Abiraterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Goserelin 10.8 mg, single dose, subcutaneously.&#xD;
Abiraterone 1,000 mg, once daily, orally for 3 months.&#xD;
Prednisone 5 mg, once daily, orally for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADT, Abiraterone and Apalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Goserelin 10.8 mg, single dose, subcutaneously.&#xD;
Abiraterone 1,000 mg, once daily, orally for 3 months.&#xD;
Prednisone 5 mg, once daily, orally for 3 months.&#xD;
Apalutamide 240 mg, once daily, orally for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <description>Androgen Deprivation Therapy</description>
    <arm_group_label>ADT and Abiraterone</arm_group_label>
    <arm_group_label>ADT, Abiraterone and Apalutamide</arm_group_label>
    <other_name>ADT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Corticosteroid</description>
    <arm_group_label>ADT and Abiraterone</arm_group_label>
    <arm_group_label>ADT, Abiraterone and Apalutamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>CYP17 inhibitor</description>
    <arm_group_label>ADT and Abiraterone</arm_group_label>
    <arm_group_label>ADT, Abiraterone and Apalutamide</arm_group_label>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>Androgen-receptor antagonist</description>
    <arm_group_label>ADT, Abiraterone and Apalutamide</arm_group_label>
    <other_name>ARN-509</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic confirmed prostatic adenocarcinoma&#xD;
&#xD;
          -  Non-castrate levels of testosterone (&gt; 150 ng/dL)&#xD;
&#xD;
          -  High-risk localized prostate cancer, defined by either:&#xD;
&#xD;
               -  Tumor stage T3 by digital rectal examination, or&#xD;
&#xD;
               -  Primary tumor Gleason score ≥ 8, or&#xD;
&#xD;
               -  PSA ≥ 20 ng/mL&#xD;
&#xD;
          -  Willing to undergo prostatectomy as primary treatment for localized prostate cancer&#xD;
&#xD;
          -  Adequate hematologic, renal and hepatic function:&#xD;
&#xD;
               -  WBC &gt; 3000/uL&#xD;
&#xD;
               -  Platelets &gt; 150,000/uL&#xD;
&#xD;
               -  Creatinine &lt; 2 mg/dL&#xD;
&#xD;
               -  Bilirubin &lt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  AST/ALT &lt; 2 x ULN&#xD;
&#xD;
          -  Karnofsky Performance Status (KPS) ≥ 80%&#xD;
&#xD;
          -  Able to swallow the study drugs whole as tablets&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pathological finding consistent with small cell, ductal or neuroendocrine carcinoma of&#xD;
             the prostate&#xD;
&#xD;
          -  Current or prior hormonal therapy, radiation therapy or chemotherapy for prostate&#xD;
             cancer&#xD;
&#xD;
          -  Evidence of metastatic disease (M1) on imaging studies&#xD;
&#xD;
          -  Other prior malignancy less than or equal to 5 years prior to randomization with the&#xD;
             exception of squamous or basal cell skin carcinoma&#xD;
&#xD;
          -  Abnormal cardiac function as manifested by NYHA (New York Heart Association) class III&#xD;
             or IV heart failure&#xD;
&#xD;
          -  History of prior cardiac arrhythmia.&#xD;
&#xD;
          -  Evidence of serious and/or unstable pre-existing medical, psychiatric or other&#xD;
             condition (including laboratory abnormalities) that could interfere with patient&#xD;
             safety or provision of informed consent to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diogo A Bastos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto do Cancer do Estado de São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01246-0000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 25, 2016</study_first_submitted>
  <study_first_submitted_qc>June 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2016</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant therapy</keyword>
  <keyword>High-risk Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

